Abstract: Providing users of an enterprise content management (ECM) system with faster and more accurate results to queries related to permission levels within the ECM system are provided by systems and methods described herein. Network traffic passing through the ECM system is listened to for changes to permission levels that a permissions manager uses to build a permissions index that is operable to provide users with up-to-date permissions levels when they interact with the ECM system.

Abstract: In one aspect, methods of treating a subject having a cancer that expresses a cytokine receptor are provided. In some embodiments, the method comprises administering to the subject a biologic agent in an amount sufficient to induce loss of cytokine receptor signaling through increased expression of a Suppressor of Cytokine Signaling genes and/or loss of one or more cytokine receptor components from the cancer cell surface. In some embodiments, the biologic agent is a cytokine or cytokine mimetic.

Abstract: Providing users of an enterprise content management (ECM) system with faster and more accurate results to queries related to permission levels within the ECM system are provided by systems and methods described herein. Network traffic passing through the ECM system is listened to for changes to permission levels that a permissions manager uses to build a permissions index that is operable to provide users with up-to-date permissions levels when they interact with the ECM system.

Abstract: Providing users of an enterprise content management (ECM) system with faster and more accurate results to queries related to permission levels within the ECM system are provided by systems and methods described herein. Network traffic passing through the ECM system is listened to for changes to permission levels that a permissions manager uses to build a permissions index that is operable to provide users with up-to-date permissions levels when they interact with the ECM system.

Abstract: Providing users of an enterprise content management (ECM) system with faster and more accurate results to queries related to permission levels within the ECM system are provided by systems and methods described herein. Network traffic passing through the ECM system is listened to for changes to permission levels that a permissions manager uses to build a permissions index that is operable to provide users with up-to-date permissions levels when they interact with the ECM system.

Abstract: A test strip for determining the concentration of a component in a liquid composition is disclosed. The test strip comprises a carrier sheet coated with a layer of an adsorbent, and a chemical dye deposited on the test strip near but spaced apart from a bottom edge of the test strip. In some embodiments, the test strip is a thin-layer chromatography (TLC) plate, and the retention factor of the chemical dye varies according to the concentration of the component in the liquid composition. A user can determine the concentration of the component based on the migration distance of the chemical dye on the test strip in a chromatography process. The test strip can be used to perform a fast and visual test to determine the ethanol content in a fuel sample.

Abstract: A luminaire can comprise an optic that extends lengthwise within a linear cavity of a frame of the luminaire. The optic can comprise a diffuser, such as a sheet of diffusing acrylic material, for example. The optic can have edges located at opposing ends of the linear cavity. The luminaire can comprise a cover for each of the two ends of the linear cavity. The covers can cover the edges of the optic, so that at each cavity end, there is an overlap between the optic and the cover. The overlap can provide a gap that compensates for thermal expansion and contraction of the optic relative to the frame, which may have a metal composition. One or more magnets can removably attach the cover to the frame of the luminaire.

Abstract: A luminaire can comprise a frame that provides a cavity for emitting illumination towards a space to be illuminated. A light source, such as a row of light emitting diodes, can emit light into the cavity. The cavity can extend lengthwise between two end caps of the frame that are located at opposing ends of the luminaire. The frame can further comprise two bridges that are located adjacent the end caps, one at each end of the frame. Two rails that extend on opposing sides of the cavity can connect the two bridges to one another. A system of grooves and protrusions can interlock the rails to the bridges. A system of standardized interchangeable components that facilitates rapid manufacture of custom luminaires can comprise the bridges, the rails, and the end caps.

Abstract: A multi-wing edge-lit structure includes a first edge-lit light guide panel, a second edge-lit light guide panel, and a joiner unit. The first edge-lit light guide panel is adjustably attached to the joiner unit on a first side of the joiner unit. The second edge-lit light guide panel is adjustably attached to the joiner unit on a second side of the joiner unit. The first side and the second side are opposite sides of the joiner unit.

Abstract: A multi-wing edge-lit structure includes a first edge-lit light guide panel, a second edge-lit light guide panel, and a joiner unit. The first edge-lit light guide panel is adjustably attached to the joiner unit on a first side of the joiner unit. The second edge-lit light guide panel is adjustably attached to the joiner unit on a second side of the joiner unit. The first side and the second side are opposite sides of the joiner unit.

Abstract: A linear light emitting diode (“LED”) light fixture includes LED modules that interface with one another to provide a substantially continuous array of LED's. This continuous array allows for substantially uniform light output from the LED light fixture. The LED modules can interface with one another via one or more connectors, which allow two or more LED modules to be electrically and mechanically coupled together. The connectors may be disposed beneath the LED's so that the connectors are not visible when the LED modules are coupled together. The connectors may be disposed along opposite ends of the modules to allow for end-to-end configurations of the modules and/or along side ends of the modules to allow for angled or curved configurations of the modules. The LED modules can be powered via one or more wires, magnets, or clips, which are coupled to a power source.

Abstract: A linear light emitting diode (“LED”) light fixture includes LED modules that interface with one another to provide a substantially continuous array of LED's. This continuous array allows for substantially uniform light output from the LED light fixture. The LED modules can interface with one another via one or more connectors, which allow two or more LED modules to be electrically and mechanically coupled together. The connectors may be disposed beneath the LED's so that the connectors are not visible when the LED modules are coupled together. The connectors may be disposed along opposite ends of the modules to allow for end-to-end configurations of the modules and/or along side ends of the modules to allow for angled or curved configurations of the modules. The LED modules can be powered via one or more wires, magnets, or clips, which are coupled to a power source.

Abstract: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent.

Abstract: The invention concerns compounds of formula (I), wherein each of R1, R2, R3, R4, R5, R6, R8, R9, R10 m, n, p, X, Y and Z have any meanings defined in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-proliferative agent in the treatment of solid tumour disease.

Abstract: The invention provides a compound of Formula (Ia), or a pharmaceutically acceptable salt, pro-drug or solvate thereof.

Abstract: The invention relates to a group of novel indole compounds of Formula (I): wherein: R1, R2, R4, R6, R6a, R7, R8, R9, R10, and A are as defined in the specification, which are useful as gonadotrophin releasing hormone antagonists. The invention also relates to pharmaceutical formulations of said compounds, methods of treatment using said compounds and to processes for the preparation of said compounds.

Abstract: The invention relates to the use of compounds of formula (I): wherein X is —C(O)—, —C(S)—, —C?NOH, or —CH(R7)— wherein R7 is hydrogen, hydroxy, C1-7alkoxy, —OR8 or —NR8R9 (wherein R8 is a group —Y1R10 (wherein Y1 is a direct bond, —C(O)—, —C(S)—, —S—, —C(O)O—, —C(O)NR11—, —SO2— or —SO2NR12— (wherein R11 and R12, which may be the same or different, each independently represents hydrogen; C1-3alkyl or C1-3alkoxyC2-3alkyl) and R10 is as defined herein, R9 includes hydrogen; R11, R12 and R13 are as defined herein and are preferably methyl; R4, R5 and R6 are as defined herein with the proviso that R5 is not hydroxy, alkoxy, substituted alkoxy, —OPO3H2, —O—C1-7alkanoyl or benzyloxy; and salts thereof in the manufacture of a medicament for use in the production of a vascular damaging effect in warm-blooded animals such as humans.

Abstract: A combination, comprising an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and an EGFR TKI, or a pharmaceutically acceptable salt thereof is described.

Abstract: The invention provides a method to automatically create high quality computer-based drawings by virtually eliminating text and graphics overwrites. This has broad practical application to a class of problems where drawings are created or updated from a non-graphic database. This is achieved through the representation of graphics as a set of bitmap images. As graphic elements are placed onto a drawing plane they contribute to the composition of a drawing's ‘committed’ bitmap. The proposed addition of new graphic elements onto the drawing plane is represented by a second ‘tentative’ bitmap. The white space algorithm uses efficient logical AND and logical OR bit manipulations to track and compare these bitmap images and determine if white space is available for placement of the proposed new graphic elements. When acceptable space is located the proposed graphics are simultaneously added to the drawing plane and inserted into the drawing's ‘committed’ bitmap.

Abstract: The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.